American Gene Technologies International
American Gene Technologies International
Company Overview
AGT has treated the first five patients with an autologous cell therapy designed to functionally cure HIV. The first patients reported no adverse events. We expect to see efficacy data this year from a handful of patients. AGT is a gene and cell therapy company working in immuno-oncology, infectious disease, and rare disease. AGT's open-label trial of an autologous cell therapy designed to cure HIV, is expected to demonstrate safety and efficacy readouts over the next nine months. Success in this study will be highly disruptive to the HIV market and create an important commercial asset for AGT. AGT’s HIV program is our near-term liquidity opportunity, and we also have two additional lead programs in phenylketonuria (PKU) and immuno-oncology (I/O). Our unique immuno-oncology approach (I/O) stimulates the natural immune system against epithelial solid tumors (breast, prostate, liver, colon, ovarian, lung, and others) and has shown promising data in animal models. With a single treatment to the primary tumor in the mice, approximately 85% achieved complete remission, including abscopal effect in secondary, metastatic, and unrelated epithelial tumors (the abscopal effect was achieved without additional treatment). Our lead collaborator on the I/O project is Dr. Dean Felsher, MD, Ph.D., Dean of Translational Research at the Stanford University School of Medicine. We believe this program will be ready for a human trial in hepatocellular carcinoma in the first half of 2021. Our technology and projects are enabled and protected by extensive IP and patents. We have patents across the HIV, PKU, and I/O projects, as well as other fundamental cornerstone innovations in the use of viral vectors and genetic constructs. This broad portfolio of elements gives AGT unique opportunities in additional infectious diseases, monogenic disorders, and cancers.
Products & Services
American Gene Technologies International - Main Product
Media Gallery
video placeholder image
American Gene Technologies International Image 1
Company Stats
Key metrics about American Gene Technologies International
Fuel Level
Engagement metrics for American Gene Technologies International
Fuel represents engagement and interest in this company from the Crowdigy community.
Are you the owner of American Gene Technologies International?
Claim your company profile to respond to reviews, update your information, and connect with investors.
Claim This Company